Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Company Growth (employees)
Cambridge, US
Size (employees)
7,400 (est)
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People at Biogen

Michel Vounatsos

Michel Vounatsos

Walter Charles

Walter Charles

Chief Procurement Officer

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St

Biogen Metrics

Biogen Financial Metrics

Revenue (2016)

$11.4 b

Revenue growth (2015-16), %


Net income (2016)

$3.7 b

Market capitalization (21-Mar-2017)

$60.2 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$2.3 b
Biogen's current market capitalization is $60.2 b.
Biogen's revenue was reported to be $11.4 b in FY, 2016 which is a 6.4% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$6.9 b$9.7 b$10.8 b$11.4 b

Revenue growth, %



$4.9 b$5.2 b

EBIT margin, %


Net Income

$1.9 b$2.9 b$3.6 b$3.7 b
FY, 2013FY, 2014FY, 2015FY, 2016


$602.6 m$1.2 b$1.3 b$2.3 b

Accounts Receivable

$824.4 m$1.3 b$1.2 b$1.4 b


$659 m$804 m$893.4 m$1 b

Current Assets

$3.2 b$4.7 b$6.7 b$8.7 b


$1.8 b$1.8 b$2.2 b$2.5 b


$1.2 b$1.8 b$2.7 b$3.7 b

Total Assets

$11.9 b$14.3 b$19.5 b$22.9 b

Accounts Payable

$219.9 m$229.2 m$267.4 m$279.8 m

Total Debt

$1.2 b

Current Liabilities

$1.8 b$2.2 b$2.6 b$3.4 b

Additional Paid-in Capital

$4 b$4.2 b

Retained Earnings

$6.3 b$9.3 b$12.2 b$15.1 b

Total Equity

$8.6 b$10.8 b$9.4 b$12.1 b

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.3 x2.1 x1.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$1.9 b$2.9 b$3.6 b$3.7 b

Depreciation and Amortization

$688.2 m$600.4 m$682.7 m

Accounts Receivable

($130 m)($510 m)$29 m($240 m)


($240 m)($190 m)($170 m)($170 m)

Accounts Payable

Purchases of PP&E

($246.3 m)($287.8 m)($643 m)($616.1 m)

Cash From Investing Activities

($1.6 b)($1.5 b)($4.6 b)($2.5 b)

Cash From Financing Activities

($716.5 m)($755.9 m)

Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Biogen Online Presence

Biogen News

Biogen Company Life

You may also be interested in